ANTIBODY THAT BINDS TO VEGF-A AND ANG2, AND METHODS OF USE Russian patent published in 2025 - IPC A61K39/395 C07K16/22 C07K16/46 A61P27/02 

FIELD: biotechnology.

SUBSTANCE: invention relates to biotechnology, in particular to an antibody or its antigen-binding fragment, which bind to human VEGF-A and to human ANG2. Also disclosed is a recovered nucleic acid coding an antibody or an antigen-binding fragment thereof, a host cell for producing an antibody or an antigen-binding fragment thereof. Invention also relates to a method of producing an antibody or an antigen-binding fragment thereof, which bind to human VEGF-A and human ANG2, and to the use of the antibody or antigen-binding fragment thereof as an angiogenesis inhibiting drug.

EFFECT: invention provides an improved therapeutic antibody which binds to VEGF and ANG2, due to higher efficacy compared to the standard of treatment and by increasing the duration of action and, in turn, reducing the frequency of intravitreal injections, which leads to a lower load on the patient.

9 cl, 10 dwg, 28 tbl, 13 ex